Kondás J, Szentgyörgyi E, Szöke D
Department of Urologic Surgery, Municipal Péterfy Sándor Street Hospital and Outpatient Clinic, Budapest, Hungary.
Int Urol Nephrol. 1988;20(6):611-5. doi: 10.1007/BF02549493.
Forty-nine patients with superficial Ta-Tl, G1-G2 vesical tumours were subjected to local Adriamycin treatment. Following transurethral resection (TUR), 50 mg doses of Adriamycin in 50 ml physiological salt solution were instilled into the bladder 4 times at intervals of one week and then 12 times at intervals of one month (i.e. a total of 15 times). Upon exclusion of two patients who failed to appear at follow-ups and one more in whom treatment was discontinued because of side effects, the remaining 46 were followed up cystoscopically for 2 years at intervals of 3 months. The recurrence rates of 12% and 24% for the primary and secondary tumours, respectively, were found to be significantly lower than those found in the control group (37% and 65%).
49例Ta-T1期、G1-G2级浅表性膀胱肿瘤患者接受了阿霉素局部治疗。经尿道切除（TUR）后，将50mg阿霉素溶于50ml生理盐水中，每周1次，共4次注入膀胱，然后每月1次，共12次（即总共15次）。排除2例失访患者和1例因副作用而停止治疗的患者后，其余46例患者每3个月进行1次膀胱镜检查，随访2年。发现原发肿瘤和继发肿瘤的复发率分别为12%和24%，显著低于对照组（37%和65%）。
